Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

9.3K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Crossover Experiments01:16

Crossover Experiments

3.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
3.7K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

157
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
157
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

185
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
185
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

409
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
409

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Neuro-oncology advances·2026
Same author

Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.

Cancer discovery·2026
Same author

Deciphering the ceRNA Network in Alfalfa: Insights into Cold Stress Tolerance Mechanisms.

Biomolecules·2026
Same author

Association between the C-reactive protein to albumin ratio and unplanned readmission in ulcerative colitis: insights from a cohort study.

Frontiers in medicine·2026

Related Experiment Video

Updated: Sep 23, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K

A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed

Yujie Zhao1, Rui Sammi Tang2, Yeting Du2

  • 1Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Biometrics
|May 13, 2022
PubMed
Summary

This study introduces a Bayesian platform trial design for efficiently evaluating multiple drugs across various diseases. The proposed method uses mixed endpoints and adaptive patient assignment to improve drug development efficiency.

Keywords:
Bayesian hierarchical modelmaster protocolmultiple indication combination therapyphase II trialsplatform design

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.7K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

737

Related Experiment Videos

Last Updated: Sep 23, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.8K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.7K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

737

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacology

Background:

  • Traditional drug development is inefficient, testing one drug at a time.
  • Targeted therapies and immunotherapies necessitate more efficient trial designs.
  • Existing methods struggle with evaluating multiple drugs in multiple indications simultaneously.

Purpose of the Study:

  • To propose a novel master-protocol-based Bayesian platform trial design with mixed endpoints (PDME).
  • To simultaneously evaluate multiple drugs across multiple indications.
  • To enhance the efficiency of modern drug development.

Main Methods:

  • Utilizes a Bayesian hierarchical model to accommodate mixed endpoints (e.g., objective response, progression-free survival).
  • Employs a two-stage approach: indication clustering followed by Bayesian modeling for information borrowing.
  • Incorporates group-sequential enrollment and adaptive patient assignment based on efficacy estimates.

Main Results:

  • The PDME design demonstrated desirable operating characteristics in simulations.
  • Effectiveness of treatments is evaluated using posterior probabilities of exceeding clinical thresholds.
  • Ineffective treatments are dropped, and effective treatments are advanced during interim analyses.

Conclusions:

  • The proposed PDME design offers a more efficient alternative to traditional drug development paradigms.
  • This adaptive Bayesian platform trial is suitable for evaluating multiple drugs in multiple indications.
  • The design facilitates precision information borrowing and adaptive treatment allocation.